Integrated proteomics and metabolomics reveal multifaceted mechanisms of colistin resistance in Acinetobacter baumanniiVisa övriga samt affilieringar
2026 (Engelska)Ingår i: Infection and Drug Resistance, E-ISSN 1178-6973, Vol. 19, s. 1-14
Artikel i tidskrift (Refereegranskat) Published
Abstract [en]
Background: The emergence of colistin-resistant Acinetobacter baumannii, particularly extensively drug-resistant carbapenem-resistant A. baumannii (XDR-CRAB), poses a critical global health threat; however, the molecular mechanisms underlying this resistance remain poorly characterized.
Methods: This study utilized integrated tandem mass tag (TMT)-based proteomics and untargeted metabolomics to compare a representative drug-sensitive (DS) strain, a colistin-sensitive multidrug-resistant (MDR-CRAB) strain, and a colistin-resistant extensively drug-resistant (XDR-CRAB) isolate from a Guangzhou hospital, China, with a primary focus on the molecular features associated with resistance in the XDR isolate.
Results: Proteomic analysis identified 260 differentially expressed proteins (DEPs) across these strains, with 98 strongly linked to the colistin-resistant phenotype. These DEPs were enriched in functions related to polysaccharide and sulfate transport, aromatic compound degradation, and cationic antimicrobial peptide (CAMP) resistance. Upregulation of the lipid A modification system, driven by increased expression of PmrA (4.2-fold), PmrB (2.9-fold), and PmrC (5.5-fold) in the XDR strain compared to the MDR strain, is consistent with this CAMP resistance. Metabolomic analysis identified 747 metabolites, with lipids and lipid-like molecules being the most altered class. The XDR strain exhibited reduced relative abundance of several glycerophospholipids and fatty acids/conjugates, when compared to the MDR strain, indicating cell membrane remodeling. Pathway enrichment analysis further implicated purine, glycerophospholipid, starch/sucrose, and glutathione metabolism in colistin resistance.
Conclusion: Colistin resistance in A. baumannii appears to involve a multifaceted strategy integrating lipid A modification, cell membrane remodeling, and metabolic reprogramming. This study provides a high-resolution molecular blueprint of colistin resistant A. baumannii and generates testable hypotheses to inform future diagnostic and therapeutic strategies against resistant infections.
Ort, förlag, år, upplaga, sidor
Taylor & Francis Group, 2026. Vol. 19, s. 1-14
Nyckelord [en]
Acinetobacter baumannii, carbapenem, colistin, extensively drug-resistant, lipid A modification, multidrug-resistant, quantitative proteomics, untargeted metabolomics
Nationell ämneskategori
Infektionsmedicin
Identifikatorer
URN: urn:nbn:se:umu:diva-249961DOI: 10.2147/IDR.S573066ISI: 001683141600001Scopus ID: 2-s2.0-105029182066OAI: oai:DiVA.org:umu-249961DiVA, id: diva2:2039419
2026-02-172026-02-172026-02-17Bibliografiskt granskad